Recombinant human insulin-like growth factor I (rhIGF-I) for the treatment of amyotrophic lateral sclerosis/motor neuron disease - Test2 - elhamkhani - TriplyDB

Recombinant human insulin-like growth factor I (rhIGF-I) for the treatment of amyotrophic lateral sclerosis/motor neuron disease

Recombinant human insulin-like growth factor I (rhIGF-I) for the treatment of amyotrophic lateral sclerosis/motor neuron disease

http://www.wikidata.org/entity/Q24197515

about

Trophic factors as modulators of motor neuron physiology and survival: implications for ALS therapy Multidisciplinary Interventions in Motor Neuron Disease.Cytoplasmic dynein heavy chain: the servant of many masters More than a bystander: the contributions of intrinsic skeletal muscle defects in motor neuron diseases.Anesthetic management of the patient with amyotrophic lateral sclerosis.Symptomatic treatments for amyotrophic lateral sclerosis/motor neuron disease.Neurotrophic and Neuroregenerative Effects of GH/IGF1.

P2860

Q26999881-D2C8F69B-F35F-470B-A959-A623B1AB81A2 Q35623262-5F56BEE4-706F-429A-BEE9-C4263CEB681A Q37298023-CFF28319-7831-4F2E-94B3-7C3FF67690AF Q37400655-6A1FD4E3-B759-4B3A-9C9A-D3EF4F38B07A Q38111222-698884F9-0ABB-4ADB-A60E-FD6F7CBDD233 Q38772250-786E17E9-3884-41FF-93FE-C39A7178A2B9 Q47152037-FD0F6BC4-8649-48AF-A85E-75569A6BD060

P2860

Recombinant human insulin-like growth factor I (rhIGF-I) for the treatment of amyotrophic lateral sclerosis/motor neuron disease

http://www.wikidata.org/entity/Q24197515

description

2012 nî lūn-bûn

@nan

2012 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Recombinant human insulin-like ...... sclerosis/motor neuron disease

@ast

Recombinant human insulin-like ...... sclerosis/motor neuron disease

@en

Recombinant human insulin-like ...... sclerosis/motor neuron disease

@en-gb

Recombinant human insulin-like ...... sclerosis/motor neuron disease

@nl

type

label

Recombinant human insulin-like ...... sclerosis/motor neuron disease

@ast

Recombinant human insulin-like ...... sclerosis/motor neuron disease

@en

Recombinant human insulin-like ...... sclerosis/motor neuron disease

@en-gb

Recombinant human insulin-like ...... sclerosis/motor neuron disease

@nl

prefLabel

Recombinant human insulin-like ...... sclerosis/motor neuron disease

@ast

Recombinant human insulin-like ...... sclerosis/motor neuron disease

@en

Recombinant human insulin-like ...... sclerosis/motor neuron disease

@en-gb

Recombinant human insulin-like ...... sclerosis/motor neuron disease

@nl

P1433

Q24197515-F0D8DD43-E9C9-4669-8D06-25D5529AEBF4

P1476

Q24197515-7D146BCC-E374-4577-ADEA-985481460B44

P2093

Q24197515-53418780-3022-490B-BAB8-374874ED765E

Q24197515-A4856872-89A9-44C1-9D35-EA5572641521

P2860

Q24197515-031B0DDF-794E-483E-B441-7AA2AEA977AC

Q24197515-0F18D788-46C1-4F75-B6D3-054570266E89

Q24197515-17824522-D72E-4E6C-8EE9-D9A2FEF1B45B

Q24197515-2D5C7338-0282-4E5E-A605-E2E71438593A

Q24197515-9329D4B9-34E0-4647-8D35-1E7EC4B4686E

Q24197515-A3A882A9-7F39-4F78-BB6C-EB931BF0BCE4

Q24197515-A5722EAB-9C95-4BEE-B9F3-B933D5BB2295

Q24197515-B25C8416-41A4-4A56-9675-F8664ED66891

Q24197515-D6C4DB28-BEB9-4885-95C8-B5BAAACBF255

Q24197515-DBE887A7-9A05-4FCD-990D-DDAF69104AFF

P304

Q24197515-AE93E8D6-BBA4-4979-86B8-5F32F16138B2

P31

Q24197515-1AA30B7C-70FD-4AA4-87CB-821FDB1A8C5A

Q24197515-87df5333-7192-4bc2-af09-d9ad18d45a34

P356

Q24197515-9184C379-5D3E-4968-ABBD-E7D2B590F17C

P478

Q24197515-AF8A56CD-448F-4AD7-8A20-C0121D3F153D

P50

Q24197515-7E0D5B6E-7633-4A26-A17F-963AFCF0AFBC

Q24197515-AF41EC53-2722-4ABA-A9D8-E6F3A27F9175

P577

Q24197515-BD2808D6-721F-4C6F-AE37-2D6141B5BD2F

P698

Q24197515-B315D513-95CB-4C75-802E-C5BEB5337DEB

P921

Q24197515-2F517600-AA3B-4FF4-888D-0067FB650A40

Q24197515-AF28A7F9-70EA-4CD4-B07C-B5159B843CDB

P356

14651858.CD002064.PUB3

P1433

Cochrane Database of Systematic Reviews

P1476

Recombinant human insulin-like ...... sclerosis/motor neuron disease

@en

P2093

J D Mitchell

http://www.w3.org/2001/XMLSchema#string

John H J Wokke

http://www.w3.org/2001/XMLSchema#string

P2860

Grading quality of evidence and strength of recommendations

Subcutaneous IGF-1 is not beneficial in 2-year ALS trial

Consensus guidelines for the design and implementation of clinical trials in ALS. World Federation of Neurology committee on Research.

Insulin-like growth factor-I: potential for treatment of motor neuronal disorders.

Beneficial effects of intrathecal IGF-1 administration in patients with amyotrophic lateral sclerosis.

Geographical epidemiology of residence of patients with motor neuron disease in Lancashire and south Cumbria.

Activity-sensitive signaling by muscle-derived insulin-like growth factors in the developing and regenerating neuromuscular system.

Distribution and levels of insulin-like growth factor (IGF-I and IGF-II) and insulin receptor binding sites in the spinal cords of amyotrophic lateral sclerosis (ALS) patients.

Nerve sprouting in innervated adult skeletal muscle induced by exposure to elevated levels of insulin-like growth factors.

Relationship of the Tufts Quantitative Neuromuscular Exam (TQNE) and the Sickness Impact Profile (SIP) in measuring progression of ALS. SSNJV/CNTF ALS Study Group.

P304

CD002064

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/14651858.CD002064.PUB3

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P50

Gian Domenico Borasio

Michel Antoine Beauverd

P577

2012-11-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23152212

http://www.w3.org/2001/XMLSchema#string

P921

amyotrophic lateral sclerosis